 |
 |
 |
 |
 |
 |
|
|
|
|
||||||||||||||
|
Management
Ram Mandalam, President & CEO Ram Mandalam, Ph.D., our President & CEO, joined the company in 2005. Ram was previously Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Prior to Geron, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications,patent applications, and abstracts. Margaret Dillon, Ph.D., our Vice President of Regulatory Affairs, joined Cellerant in October 2010 with 19 years of regulatory experience in the biopharmaceutical industry. Previously, she worked at CV Therapeutics, Inc. for 9 years, serving most recently as Vice President, Regulatory Affairs. During this period, Margaret was involved with the development and US/EU marketing approvals for two new chemical entities for cardiovascular indications. Prior to this, Margaret was part of the regulatory groups at SyStemix, Inc., Connetics, Inc., and Schering-Plough Research Institute. Margaret holds a B.S. in Chemistry from SUNY Albany and a Ph.D. in Biochemical Pharmacology from SUNY Buffalo. Robert Tressler, Ph.D., our Vice President of Research & Development, joined the company in January, 2011. He has over 20 years of industry experience in oncology, cardiovascular and age-related disorders. Previously Dr. Tressler was Executive Director of Preclinical Research and Development at Geron Corporation, where he led the discovery research and preclinical development with oversight of Geron's telomerase inhibitor and cancer stem cell programs. Prior to Geron, he held multiple preclinical pharmacology leadership roles in the biotechnology sector, including Matrix Pharmaceuticals, Chiron, Syntex and Ligand Pharmaceuticals, establishing multidisciplinary preclinical research and development teams focusing on oncology-based therapeutics as well as participating in IND and NDA filings for oncology development programs. Dr. Tressler received his M.S. in Microbiology from McNeese State University and his Ph.D. in Cancer Biology from the University Of Texas Graduate School Of Biomedical Sciences at M.D. Anderson Cancer Center, and has co-authored over 20 peer-reviewed scientific articles, book chapters and reviews as well as giving numerous invited talks and presentations at national and international scientific meetings. Dr. Tressler also holds multiple patents for oncology-based therapeutics. Jun S.Yoon, our Executive Director of Corporate Development, joined the company in 2010. Jun recently served as Sr. Director, Licensing & Business Development at VIA Pharmaceuticals from 2004 to 2010. He was responsible for in-licensing VIA's programs and managed VIA's business development activities. Previously, he was Manager, Business Development at Sagres Discovery until it was acquired in May 2004 by Chiron Corporation. Mr. Yoon had joined Sagres from its merger with MemRx Corporation, a biotechnology company focused on the structure based drug discovery of membrane proteins. Prior to Sagres/MemRx, Mr. Yoon was Manager, Business Development at Syrrx, a structure based drug discovery company based in San Diego, which had been acquired by Takeda Pharmaceutical Co., Ltd. He was one of the earliest employees of Syrrx and had been responsible for in-licensing technologies and compounds. Prior to Syrrx, Mr. Yoon was conducting structural biology research at The Scripps Research Institute. Mr. Yoon received a B.A. in Molecular Cell Biology from UC Berkeley. |
||||||||||||||||